PDF(Pubmed)
Abstract：
OBJECTIVE: To investigate the effects of the combined application of percutaneous vertebroplasty and zoledronic acid on bone mineral density (BMD), bone metabolism, neuropeptide Y (NPY) and prostaglandin E2 (PGE2) in elderly patients with osteoporotic lumbar vertebral compression fracture (OVCF).
METHODS: The medical records of 118 elderly patients with OVCF who received treatment at our hospital from March 2018 to March 2020 were collected and analyzed retrospectively. Vertebral body height, spinal function, pain degree, and lumbar BMD were compared between the two groups upon admission and three years after the operation. Additionally, the levels of bone-specific alkaline phosphatase (BALP), 25-hydroxyvitamin D (25-(OH)D), beta collagen degradation fragments (β-CTx), neuropeptide Y (NPY), and prostaglandin E2 (PGE2) in the two groups were measured at admission and three years after the operation. Furthermore, complications in the two groups within three years after the operation were documented.
RESULTS: After three years post-operation, the combination group showed a significantly greater improvement in vertebral body height compared to the control group (P<0.05). Moreover, the combination group exhibited a significantly lower Oswestry Disability Index (ODI) score compared to the control group (P<0.05).
CONCLUSIONS: In elderly patients with OVCF, the combined use of zoledronic acid and percutaneous vertebroplasty is effective in improving lumbar function, BMD, and bone metabolism indices, while reducing pain and the levels of NPY and PGE2.
METHODS: The medical records of 118 elderly patients with OVCF who received treatment at our hospital from March 2018 to March 2020 were collected and analyzed retrospectively. Vertebral body height, spinal function, pain degree, and lumbar BMD were compared between the two groups upon admission and three years after the operation. Additionally, the levels of bone-specific alkaline phosphatase (BALP), 25-hydroxyvitamin D (25-(OH)D), beta collagen degradation fragments (β-CTx), neuropeptide Y (NPY), and prostaglandin E2 (PGE2) in the two groups were measured at admission and three years after the operation. Furthermore, complications in the two groups within three years after the operation were documented.
RESULTS: After three years post-operation, the combination group showed a significantly greater improvement in vertebral body height compared to the control group (P<0.05). Moreover, the combination group exhibited a significantly lower Oswestry Disability Index (ODI) score compared to the control group (P<0.05).
CONCLUSIONS: In elderly patients with OVCF, the combined use of zoledronic acid and percutaneous vertebroplasty is effective in improving lumbar function, BMD, and bone metabolism indices, while reducing pain and the levels of NPY and PGE2.
摘要：
目的：探讨经皮椎体成形术联合唑来膦酸对骨密度的影响。骨代谢，神经肽Y（NPY）和前列腺素E2（PGE2）在老年骨质疏松性腰椎压缩性骨折（OVCF）中的作用。
方法：收集2018年3月至2020年3月在我院接受治疗的118例老年OVCF患者的病历资料进行回顾性分析。椎体高度,脊髓功能,疼痛程度,比较两组入院时及术后3年的腰椎骨密度。此外,骨特异性碱性磷酸酶（BALP）的水平，25-羟基维生素D(25-(OH)D),β胶原降解片段（β-CTx），神经肽Y（NPY），两组患者入院时及术后3年测定前列腺素E2(PGE2)。此外，记录两组术后3年内的并发症.
结果：手术后三年，与对照组相比，联合组椎体高度改善明显（P<0.05）。此外，与对照组相比，联合组的Oswestry残疾指数（ODI）评分显着降低（P<0.05）。
结论：在老年OVCF患者中，唑来膦酸联合经皮椎体成形术可有效改善腰椎功能,BMD,和骨代谢指标，同时减轻疼痛和NPY和PGE2的水平。
方法：收集2018年3月至2020年3月在我院接受治疗的118例老年OVCF患者的病历资料进行回顾性分析。椎体高度,脊髓功能,疼痛程度,比较两组入院时及术后3年的腰椎骨密度。此外,骨特异性碱性磷酸酶（BALP）的水平，25-羟基维生素D(25-(OH)D),β胶原降解片段（β-CTx），神经肽Y（NPY），两组患者入院时及术后3年测定前列腺素E2(PGE2)。此外，记录两组术后3年内的并发症.
结果：手术后三年，与对照组相比，联合组椎体高度改善明显（P<0.05）。此外，与对照组相比，联合组的Oswestry残疾指数（ODI）评分显着降低（P<0.05）。
结论：在老年OVCF患者中，唑来膦酸联合经皮椎体成形术可有效改善腰椎功能,BMD,和骨代谢指标，同时减轻疼痛和NPY和PGE2的水平。
